Who Paid My Doc
Phase 3 substudy enrolling approximately 100 subjects aged 18 to 70 years old with PKU who are concurrently participating in the 165-302 study
Research payments
$5,582,650
Through program year 2024, $5,582,650 in research payments was reported against Phase 3 substudy enrolling approximately 100 subjects aged 18 to 70 years old with PKU who are concurrently participating in the 165-302 study, across 405 payments, paid by BioMarin Pharmaceutical Inc..
- Paid by
- BioMarin Pharmaceutical Inc.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | Research | $2,578,348 | 178 |
| 2023 | Research | $2,623,494 | 152 |
| 2022 | Research | $380,807 | 75 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
7 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Christina Peroutka Charlottesville, VA Named on 40 payments
- Amarilis Sanchez Valle Tampa, FL Named on 40 payments
- Hope Northrup Houston, TX Named on 37 payments
- Melissa Lah Indianapolis, IN Named on 35 payments
- Gerard Vockley Pittsburgh, PA Named on 17 payments
- Thomas Burrow Little Rock, AR Named on 14 payments
- Stephanie Offord Milwaukee, WI Named on 13 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.